Post-cycle therapy in plain English — what it is and why it matters
9 min read · Uplevel editorial
You've stopped. Whether you made the decision yourself, were advised to by a provider ending a supervised TRT course, or simply reached the point where the consequences outweighed the benefits — you've come off exogenous testosterone or anabolic steroids, and now you're waiting for your body to restart something it stopped doing while the external supply was running. The waiting is not comfortable. Energy is low. Mood is poor in the particular way that insufficient testosterone produces — not quite depression, more like a sustained deflation, a thinning of the world. Libido is absent. The body feels different and not in a good way. You've been told it'll come back on its own, and that's true in principle. In practice, the question of how long, how completely, and what you can do to support the process — these are questions that deserve real answers rather than reassurance.
The HPG axis suppression that comes with exogenous androgen use is the inevitable consequence of the feedback system doing exactly what it was designed to do. The hypothalamus detects elevated androgens in the blood. It reduces GnRH output. The pituitary, receiving less GnRH, reduces LH and FSH. The testes, receiving little or no LH signal, stop producing testosterone. The Sertoli cells, receiving little FSH, stop supporting spermatogenesis. Over weeks and months of this suppression, the testes atrophy — physically smaller, and functionally reduced at the level of Leydig cell activity and receptor density. The hypothalamus and pituitary, having been in a low-output state for the duration of use, need time to recognize that the external androgen supply has been removed and to gradually increase their output again. None of this happens quickly, and none of it is automatic in the sense of being rapid. Left entirely to its own devices, the HPG axis can take six months, a year, sometimes longer to restore something like its prior function. In men with prolonged exposure — years of use, especially at higher doses — full recovery of baseline endogenous production may not occur. This is not a common scare story. It is a real clinical outcome, and it's the reason post-cycle therapy exists.
The goal of PCT is to accelerate and support the axis restart rather than waiting passively for spontaneous recovery. It operates on several levels simultaneously, because the suppression affects multiple components of the same cascade, and restoring function requires addressing more than one point of dysfunction.
SERMs — selective estrogen receptor modulators — are the backbone of most PCT protocols, and their mechanism is specific to the pituitary level. When exogenous androgens are removed, estradiol often remains elevated for a period relative to testosterone (because aromatase activity persists, and because the remaining estradiol has a longer half-life than testosterone in some contexts). Elevated estradiol at the pituitary continues to suppress LH release through estrogen feedback, perpetuating the low-LH, low-testosterone state even after the external androgens are gone. SERMs — clomiphene, tamoxifen, enclomiphene — block the estrogen receptor at the pituitary, removing this feedback brake and allowing LH to begin rising. As LH rises, Leydig cells receive stimulation and begin producing testosterone again. Clomiphene has been the most widely used for this purpose; enclomiphene, the active trans-isomer, avoids some of the estrogenic effects of the cis-isomer component in racemic clomiphene and has been studied specifically in the hypogonadotropic hypogonadism context with favorable results. These are prescription medications, not supplements. Their use in PCT protocols should be managed by a prescribing provider, with monitoring.
HCG addresses a different level of the same problem: the testes themselves. While SERMs act at the pituitary to increase LH signal, the testes that have been in a suppressed state for months or years need direct stimulation to recover Leydig cell function. HCG, binding to the LH receptor on Leydig cells, provides that direct stimulation independently of what's happening upstream. Many clinical PCT protocols use HCG in the initial phase — while LH is still low and endogenous signaling is just restarting — to begin restoring testicular function from the bottom of the cascade simultaneously with the SERM-driven pituitary restart from above. The sequencing matters: HCG is typically used first or alongside the early SERM phase, not indefinitely, because prolonged HCG use without eventual transition to SERM-based protocols can itself desensitize Leydig cells.
FSH — or FSH stimulation through clomiphene's effects on pituitary output — addresses spermatogenesis specifically. FSH is the signal that supports Sertoli cell function and the spermatogenic process. In men coming off anabolic steroids who want to restore fertility as well as testosterone production, FSH recovery is a distinct consideration from LH and testosterone recovery. The two processes are related — adequate intratesticular testosterone (driven by LH/HCG) is required for spermatogenesis — but FSH is the more direct driver, and in some post-cycle cases where LH and testosterone recover but sperm counts remain low, FSH-specific support with recombinant FSH or continued clomiphene becomes the focus.
Aromatase inhibitors — anastrozole, letrozole — are sometimes included in PCT protocols to manage estradiol, but this is a more nuanced application than it sounds. Some aromatase inhibition may be warranted if estradiol is clearly elevated and creating ongoing pituitary suppression, but over-suppression of estradiol carries its own costs: estradiol is required for bone health, libido, mood, and cardiovascular function. The goal is not to eliminate estradiol. It is to keep it in a range that allows the pituitary to receive reduced feedback while preserving the functions that adequate estradiol supports. This is an area where self-directed PCT protocols commonly go wrong — using aromatase inhibitors too aggressively, driving estradiol too low, and producing symptoms that are worse than the original post-cycle presentation.
The kisspeptin-10 research interest in this context is worth noting. Kisspeptin sits upstream of GnRH in the hypothalamic control of the reproductive axis, and research in men with hypogonadotropic hypogonadism suggests that kisspeptin administration can drive LH pulsatility when the GnRH pulse generator has been dormant. The theoretical application to post-cycle axis restart — reactivating a hypothalamic pulse generator that has been suppressed — is biologically coherent, though the clinical application is early and not yet established as a standard approach.
There is a harm reduction dimension here that deserves direct acknowledgment. A substantial number of men who find themselves needing PCT are not coming off medically supervised TRT. They are coming off anabolic steroids used in athletic or physique contexts, often obtained outside the medical system, often at doses and with compounds that exceed anything a clinical provider would prescribe. The HPG axis suppression in these cases is often more severe — longer duration, higher doses, often multiple agents, sometimes compounds with prolonged half-lives. The approach of simply waiting for spontaneous recovery is particularly inadequate in this population, and the risk of permanent or prolonged hypogonadism is meaningfully higher. This is not a judgment about the choice. It is a statement about the clinical reality, and about the importance of medical supervision for the restart process even for people whose use was not medically supervised.
The legitimate clinical context for PCT is equally real: men who have completed supervised TRT and are discontinuing — because they want to pursue fertility, because they've made a quality-of-life decision to try restoring endogenous production, or because their clinical picture has changed — deserve a structured, monitored restart protocol rather than abrupt cessation and watchful waiting. The monitoring piece matters: serial testosterone, LH, FSH, and estradiol measurements over weeks and months allow the protocol to be adjusted as the axis responds, and allow detection of cases where recovery is not proceeding as expected. Without monitoring, there's no way to know whether the axis is recovering or stalling.
What PCT cannot do — and should not be presented as doing — is guarantee complete recovery of baseline function in all cases. For men with prolonged, high-exposure histories, some degree of permanent HPG axis dysfunction is a recognized outcome in the research literature. Awareness of this risk before beginning any anabolic regimen is a meaningful part of informed decision-making. Awareness of it after the fact — when the question is how to best support whatever recovery is possible — is the starting point for a realistic clinical conversation. That conversation, like all of this, belongs in the office of a prescribing provider who understands HPG axis physiology and can manage the protocol with the monitoring and adjustments it requires.
Frequently asked